Active (not recruiting) Phase 2 2025-521828-30-00

Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

Phase 2 – studying effectiveness and dosage

Conditions: Advanced Solid Tumors

Sponsor: Pyxis Oncology Inc.

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 21 participants

France (1)

Poland (1)

Spain (1)

Status

Active (not recruiting)

Phase

Phase 2

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Healthy volunteers

Start date

19.11.2025

Registry ID

2025-521828-30-00

Source

euclinicaltrials.eu

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.